Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team. Nyaku AN, et al. Among authors: zheng l. J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564. J Antimicrob Chemother. 2019. PMID: 30668695 Free PMC article. Clinical Trial.
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.
Smith K, Zheng L, Bosch R, Margolis DM, Tenorio A, Napolitano L, Saag M, Connick E, Gross B, Francis I, Valdez H, Muurahainen N, Stocker V, Pollard R. Smith K, et al. Among authors: zheng l. AIDS Res Hum Retroviruses. 2010 Apr;26(4):425-32. doi: 10.1089/aid.2009.0052. AIDS Res Hum Retroviruses. 2010. PMID: 20415638 Free PMC article. Clinical Trial.
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team. Gandhi RT, et al. Among authors: zheng l. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2. J Acquir Immune Defic Syndr. 2012. PMID: 22083073 Free PMC article. Clinical Trial.
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.
Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W; ACTG A5262 Study Team; Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings A. Li JZ, et al. Among authors: zheng l. PLoS One. 2014 Mar 6;9(3):e90485. doi: 10.1371/journal.pone.0090485. eCollection 2014. PLoS One. 2014. PMID: 24603872 Free PMC article. Clinical Trial.
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.
Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team. Jacobson JM, et al. Among authors: zheng l. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):399-406. doi: 10.1097/QAI.0000000000000195. J Acquir Immune Defic Syndr. 2014. PMID: 24815851 Free PMC article. Clinical Trial.
16,452 results
You have reached the last available page of results. Please see the User Guide for more information.